• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract P480: Effects Of Long And Intermediate Acting Dihydropyridine Calcium Channel Blockers In Hypertension: A Systematic Review And Aeta-analysis Of 18 Prospective, Actively Controlled, Randomized Clinical Trials Session Title: Antihypertensive Drugs and Pharmacology, Patient-Provider-Healthcare System Issues, and Pediatric and Adolescent Hypertension
Conclusions: This study suggests that Amlodipine offers greater protection against major complications of hypertension compared to intermediate acting dihydropyridine calcium channel blockers.
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Sandip Chaugai, Hisatomi Arima, Lhamo Yangchen Sherpa, Amir Sepehry Tags: Poster Abstract Presentations Source Type: research

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)Novelty and Significance Clinical Trials
Randomized trials of hypertension have seldom examined heterogeneity in response to treatments over time and the implications for cardiovascular outcomes. Understanding this heterogeneity, however, is a necessary step toward personalizing antihypertensive therapy. We applied trajectory-based modeling to data on 39 763 study participants of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to identify distinct patterns of systolic blood pressure (SBP) response to randomized medications during the first 6 months of the trial. Two trajectory patterns were identified: immediate responde...
Source: Hypertension - June 7, 2017 Category: Cardiology Authors: Sanket S. Dhruva, Chenxi Huang, Erica S. Spatz, Andreas C. Coppi, Frederick Warner, Shu-Xia Li, Haiqun Lin, Xiao Xu, Curt D. Furberg, Barry R. Davis, Sara L. Pressel, Ronald R. Coifman, Harlan M. Krumholz Tags: Cardiovascular Disease, Hypertension, Quality and Outcomes Original Articles Source Type: research

Critical Blood Pressure Threshold Dependence of Hypertensive Injury and Repair in a Malignant Nephrosclerosis Model Kidney
Most patients with essential hypertension do not exhibit substantial renal damage. Renal autoregulation by preventing glomerular transmission of systemic pressures has been postulated to mediate this resistance. Conversely, malignant nephrosclerosis (MN) has been postulated to develop when severe hypertension exceeds a critical ceiling. If the concept is valid, even modest blood pressure (BP) reductions to below this threshold regardless of antihypertensive class (1) should prevent MN and (2) lead to the healing of the already developed MN lesions. Both predicates were tested using BP radiotelemetry in the stroke-prone spo...
Source: Hypertension - September 10, 2014 Category: Cardiology Authors: Griffin, K. A., Polichnowski, A., Litbarg, N., Picken, M., Venkatachalam, M. A., Bidani, A. K. Tags: Animal models of human disease Kidney Source Type: research

The Value of N-Terminal Pro-B-Type Natriuretic Peptide in Determining Antihypertensive Benefit: Observations From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Natriuretic Peptides
We investigated 3 hypotheses: (1) N-terminal pro–B-type natriuretic peptide (NT-proBNP) predicts cardiovascular disease events in patients with hypertension, (2) NT-proBNP is associated with blood pressure variability, and (3) NT-proBNP predicts benefit from antihypertensive regimens. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) randomized a subset of 6549 patients at risk with no history of coronary heart disease to either atenolol-based or amlodipine-based blood pressure–lowering treatment. During 5.5 years of follow-up, 485 cardiovascular disease cases accrued and were matched with 1367 controls. Ba...
Source: Hypertension - February 12, 2014 Category: Cardiology Authors: Welsh, P., Poulter, N. R., Chang, C. L., Sever, P. S., Sattar, N., on behalf of the ASCOT Investigators Tags: Cerebrovascular disease/stroke Natriuretic Peptides Source Type: research

Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex Clinical Trial - ALLHAT
To determine whether an angiotensin-converting enzyme inhibitor (lisinopril) or calcium channel blocker (amlodipine) is superior to a diuretic (chlorthalidone) in reducing cardiovascular disease incidence in sex subgroups, we carried out a prespecified subgroup analysis of 15 638 women and 17 719 men in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Total follow-up (active treatment + passive surveillance using national administrative databases to ascertain deaths and hospitalizations) was 8 to 13 years. The primary outcome was fatal coronary heart disease or nonfatal myocardial i...
Source: Hypertension - April 17, 2013 Category: Cardiology Authors: Oparil, S., Davis, B. R., Cushman, W. C., Ford, C. E., Furberg, C. D., Habib, G. B., Haywood, L. J., Margolis, K., Probstfield, J. L., Whelton, P. K., Wright, J. T., for the ALLHAT Collaborative Research Group Tags: Primary prevention, Secondary prevention, Clinical Studies Clinical Trial - ALLHAT Source Type: research